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Abstract
Background: Venous thromboembolism prophylaxis has been shown to safely and cost-effectively reduce the
incidence of thromboembolic events in medical inpatients. However, there is a gap between evidence and medical
practice. The aim of this study was evaluate the appropriateness of prescribing venous thromboembolism
prophylaxis in accordance with local recommendations for medical inpatients.
Methods: This cross-sectional study included 310 prescriptions of medical general-ward admitted patients of two
university hospitals of Buenos Aires, Argentina.
Data was collected using filled-out prescriptions, medical records and interviews with the head attending physician.
Information was gathered at different times during 16 days randomly selected over September 2007 and January
2008.
Results: One hundred eighty eight patients’ prescriptions (60.6%) were appropriate according to the institutional
guidelines. Inappropriateness was due to excessive (14.2%), insufficient (15.8%) and absent (9.4%) prescribing.
According to the recommendations of the American College of Chest Physicians, 256 (82.6%) patients received
appropriate prophylaxis. Twenty-nine patients (9.4%) were considered at low risk for thromboembolism and did
not need pharmacologic or mechanical prophylaxis. One hundred three patients (33.2%) had at least one major
risk factor for venous thromboembolism. Compliance with the institutional guidelines was more frequently in the
case of high risk patients. Complex preventive measures and low risk patients were related to lower adherence to
recommendations. In the multivariate analysis, predictors of inappropriateness were the requirement of a surgical
procedure and absence of prophylaxis prescribing at admission. In contrast, patients with a diagnosis of
gastrointestinal disorders had lower odds of inappropriateness than those with an infectious disease.
Conclusions: Most medical inpatients received some thromboprophylaxis measure, but the compliance with
recommendations was less frequent. Efforts should be made to improve the appropriate prescription.
Background
Venous thromboembolism (VTE) is considered the most
common preventable cause of hospital-related death [1].
Before preventive measures for VTE were implemented,
it was estimated that 10% of hospital deaths were asso-
ciated with VTE [2]. Moreover, patients who survive the
early event present a mortality rate of approximately
17% at 3 months [3] and may develop long-term com-
plications including recurrent VTE, post-thrombotic
syndrome, and chronic thromboembolic pulmonary
hypertension [4]. More than half of hospital-VTE cases
occur in patients admitted for non-surgical conditions
[5].
VTE prophylaxis has been shown to cost-effectively
reduce the incidence of thromboembolic events in medi-
cal inpatients [6-9]. For this reason, since 1986, the
American College of Chest Physicians (ACCP) regularly
reports recommendations for the prevention of VTE
[10]. Many hospitals and institutions develop local
guidelines or adapt those published by ACCP to their
own context [11-13]. Despite all the efforts, there is a
large gap between clinical practice guidelines (CPG) and
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the recommendations on VTE prophylaxis varies
between 16 and 60% [5,14,15].
The appropriate prescription of thromboprophylaxis
not only can prevent VTE, but it also can serve as an
indicator of both health care quality and patient safety.
Recognizing the need to improve prevention and care
of VTE, public agencies and others organizations, such
as the National Quality Forum, The Joint Commission,
and the Agency for Healthcare Research and Quality,
have included VTE prophylaxis as one of the central
medical practices to improve patient safety [16-18].
In Argentina, little data exist regarding physicians’
compliance with VTE prophylaxis CPG. The purpose of
this study is to evaluate the appropriateness of VTE pro-
phylaxis prescription in accordance with the local
recommendations for medical inpatients in two univer-
sity hospitals in Buenos Aires. And also to describe the
errors made and to analyze the variables associated with
the lack of compliance with recommendations.
Methods
Setting
This study was carried out in two university hospitals
that are part of the same institution, located in the city
of Buenos Aires (Argentina).
Both hospitals share the same personnel. Paper based
prescriptions are usually issued by first-year residents
and supervised by the senior residents and the attending
physicians. The team on call daily assess patient’sr i s k
factors and prophylaxis contraindications listed in the
CPG and prescribe VTE prophylactic measures accord-
ing with the institutional recommendations.
Institutional VTE-prophylaxis CPG
Both centers share the same VTE prophylaxis CPG. An
institutional multidisciplinary group composed of medi-
cal members from the departments of emergency, hema-
tology, and internal medicine developed and updated the
VTE prophylaxis CPG based on accepted scientific stan-
dards and guidelines [10-13]. Distribution of these
recommendations were done annually using pocket size
booklets and educational talks. Reminders were placed
in areas where the prescriptions are usually filled out
and in pre-designed paper-based prescriptions. Also
audit and feedback about the appropriateness of VTE-
prophylaxis practice were performed.
The local CPG define 5 risk groups according to each
patient’s risk for VTE and any contraindications. Pre-
scription recommendations of a specific mechanical and/
or pharmacologic prophylaxis measures are as follows:
-Group A (patients with any major risk factor for
VTE): low molecular weight heparin (LMWH) 4000 IU
(international units) Anti Xa/day.
-Group B (patients with four or more risk factors for
VTE): unfractionated heparin (UFH) 5000 IU/8 hours or
UFH 7500 IU/12 hours.
-Group C (patients with 2 or 3 risk factors for VTE):
UFH 5000 IU/12 hours.
-Group D (patients with any major risk factor for
VTE, who recently underwent surgery and were
anesthetized for more than 2 hours): LMWH 4000 UI
Anti Xa/day plus a mechanical prophylactic measure.
-Group E (patients with no or only one risk factor for
VTE): no prophylaxis is recommended.
In the case of patients belonging to groups A to D
who have contraindications for pharmacologic prophy-
laxis, the use of mechanical prophylaxis is recommended
instead. The institutional CPG define the following con-
ditions as major risk factors: cancer, prior VTE, severe
limb paresis or paralysis, thrombophilia, major trauma,
severe inferior limb trauma, knee or hip surgery. In
addition, they define the following as (non-major) risk
factors: immobility (perception of treating physician that
the patient will be confined to bed for more than 48
hours, excepting mobilization to toilet), age over 40
years, heart failure, body mass index > 30, respiratory
failure, acute myocardial infarction, sepsis, estrogen
therapy, travel by car or plane for more than 4 hours in
the previous week, delivery during the last month,
family history of VTE, surgery, central lines, chemother-
apy, burns, stroke, inflammatory bowel disease, mild
trauma, and myeloproliferative syndromes.
Contraindications for pharmacological prophylaxis
included: platelet count < 100,000/μL, heparin-induced
thrombocytopenia, active bleeding, severe coagulophaty,
malignant hypertension, trauma with high risk for bleed-
ing, hemorrhagic stroke in the last 15 days and hemi-
spheric ischemic stroke in the last 72 hours.
Contraindications for mechanical prophylaxis included:
cellulitis, gangrene or recent skin grafting on inferior
limb, severe peripheral vascular disease and heel decubi-
tus ulcer.
Design, study population and information sources
This cross-sectional study was conducted between Sep-
tember 2007 and January 2008.
Prescriptions of medical general-ward admitted
patients issued by the internal medicine physicians of
both centers were included. Prescriptions were excluded
in the case of (1) patients under 16 years old, (2) preg-
nant women, (3) patients who had received recent fibri-
nolytic therapy or (4) were currently treated with
anticoagulant therapy, (5) patients hospitalized for less
than 24 hours, (6) patients who had undergone neuro-
surgery, (7) those who were under palliative care, (8)
patients already included in the study during the
ongoing hospitalization and (9) patients hospitalized in
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gery, obstetrician and paediatrician wards).
Data was collected using medical records, filled-out
prescriptions and interviews with the head attending
physician, if necessary (see below). Information was
gathered at different times during 16 days randomly
selected over the 4-month study period.
Variables
Medical prescriptions were considered “appropriate”
when VTE prophylaxis was prescribed according to the
institutional CPG recommendations at the time of
recruitment. Otherwise, prescriptions were considered
“inappropriate”. Inappropriate prescriptions were classi-
fied into the following exclusive categories:
a) Excessive prescription: use of a VTE prophylactic
measure that was unnecessarily more effective, complex
or redundant than those recommended by the institu-
tional guidelines.
b) Insufficient prescription: use of a VTE prophylactic
measure that was less effective, complex or complete
than those recommended by the institutional guidelines.
Those prescriptions lacking prophylactic measures were
excluded from this category.
c) Absent prescription: No prophylaxis measure was
prescribed when recommended.
We also evaluated if prescription error was due to
inappropriate drug, dose or dose interval, disregarded
contraindications, lack of pharmacologic or mechanical
prophylaxis, unnecessary mechanical or pharmacologic
prophylaxis and others causes.
Furthermore, in case of inappropriate prophylaxis, the
error was analyzed by consulting the medical records
and an immediate interview with the head attending
physician. The purpose of this interview was to deter-
mine whether the inappropriate prescription was based
on any clinical grounds that went unreported in the
medical record or prescription.
Apart from the type of prophylaxis prescribed and
recommended by the institutional CPG, other variables
were registered: (1) socio-demographic data, (2) pre-
sence of major or non-major risk factors for VTE (3)
presence of contraindication for the use of heparins,
graduated compression stockings (GCS) or intermittent
pneumatic compression devices (IPC), (4) date, time,
center and diagnosis at admission, (5) weight under 40
kg, (6) renal failure with glomerular filtration rate < 30
ml/min – Cockcroft-Gault formula [19], (7) data of the
physician who prescribed the prophylaxis, (8) disconti-
nuation of prophylaxis at any time during hospitaliza-
tion, (9) prophylaxis prescription within 24 hours of
admission, (10) changes in prophylactic regimen during
hospitalization, and (11) stay at the intensive care units
(ICU) during the ongoing hospitalization.
Ethical considerations
In order to preserve patients’ safety, the head attending
physician was notified of the errors encountered and
asked to make the necessary changes according to his/
her clinical judgment. Confidentiality of both, the
patients and the physicians, was ensured. This study was
approved by the Institutional Review Board.
Statistical analysis
Categorical variables were compared using Chi-squared
test or Fisher exact test.
Normally distributed continuous variables were com-
pared using t-Test, otherwise Mann-Whitney test was
used. All of them were two tailed-tests. Predictors of
inappropriate prescribing were assessed using a multiple
logistic regression analysis. Independent variables con-
sidered to be clinically relevant or statistically significant
(p < 0.1) in the univariate analysis were included in the
model. Patients categorized as risk Group D were not
included. We accepted a statistical significance of 95%.
SPSS 13.0.2004 software was used (SPSS, Inc., Chicago,
IL, USA).
Results
Study Population
A total of 584 medical prescriptions were evaluated, and
2 7 4w e r ee x c l u d e d( 1 9 4[ 7 0 , 8 % ]w e r ef r o mp a t i e n t s
already included in the study during the ongoing hospi-
talization, 65 [23,7%] were currently treated with antic-
oagulant therapy and 15 [5,5%] had others exclusion
criteria). Thus, 310 medical prescriptions were included
in this study.
The patient characteristics of the included prescrip-
tions are summarized in Table 1. One hundred twenty
four patients (40%) were hospitalized due to infectious
diseases (40 patientes had pneumonia and 22 urinary
tract infection). Seventy patients (23%) required hospita-
lization in ICU. One third of the population had at least
one major risk factor for VTE, seventy four (72%) of
these patients presented cancer and fifteen (15%) had
severe limb paresis or paralysis. Non-major risk factors
included immobility 268 (86%) patients, age over 40
years 260 (84%), sepsis 117 (38%), surgery 38 (12.6%)
and heart failure 28 (9%). Other risk factors were
observed in less than 5% of the patients. Twenty nine
patients (9.4%) had less than 2 risk factors and thus did
not require thromboprophylaxis (Risk group E). Only six
patients required both pharmacologic and mechanical
prophylaxis (1.9%) Risk group D.
Prescription Appropriateness
According to the institutional guidelines, VTE prophy-
laxis was appropriately prescribed to 188 patients
(60.6%). Inappropriate prescribing was due to excessive
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tion. Rates and reasons of inappropriateness differed
among risk groups (Figure 1).
Group A had 76 (77.6%) appropriate prescriptions. In
this group, 50% of inappropriate prescriptions had insuf-
ficient prophylaxis, while 40% lacked all prophylactic
measures. Of the 9 patients without prophylaxis, 7 had
contraindications for pharmacologic prophylaxis (6 due
to thrombocytopenia and 1 due to active bleeding) and
no mechanical prophylaxis prescribed. Thirty eight
patients in Group B (44.7%) had appropriate prescrip-
tions. In this group, two thirds of the inappropriate pre-
scriptions had insufficient prophylaxis prescribed.
Although Group C had 59 (64%) appropriate prescrip-
tions, it had the highest rate of absent prescriptions
(40% of inappropriate prescriptions).
In Group D (n = 6), none of the prescriptions were
appropriate. In 5 cases (83%) mechanical measures were
not prescribed. Finally, Group E showed 15 (51.7%)
appropriate prescriptions. Inappropriate prescriptions
were all due to excessive mechanical or pharmacologic
prophylaxis.
Thirty nine (72%) patients with contraindications for
pharmacologic prophylaxis had an appropriate VTE-pre-
scription. In these patients, the absence of mechanical
prophylaxis was the most frequent error observed (73%
of inappropriate prescriptions). The interviews with the
head attending physician revealed that only 11 (3.5%) of
inappropriate prescriptions were based on clinical judg-
ment, aware that recommendations were not being fol-
lowed. We found that 256 (82.6%) prescriptions were
appropriate according to the ACCP recommendations.
Use of VTE Prophylaxis
Two hundred and sixty five patients (85.5%) received
thromboprophylaxis. Drugs and doses prescribed
included UFH 5000 IU every 12 hours (31.3%), UFH
5000 IU every 8 hours in (8.1%), UFH 7500 IU every 12
hours in (6.5%), LMWH 4000 UI anti Xa every 24 hours
in (25.2%), and others not mentioned in the guidelines
in (1%). Moreover, GCS were used on 41 patients
(13.2%) and IPC in one case.
Figure 2 shows the prophylaxis recommended by
guidelines and that actually prescribed during the study.
The prescription of UFH 5000 IU every 8 hours or UFH
7500 IU every 12 hours was lower than that recom-
mended. (p < 0,001)
Predictors of inappropriateness
Table 2 shows that several variables were associated
with the appropriateness of VTE-prophylaxis prescrip-
tion: surgery, VTE prescription at admission, risk group,
the fact of being enrolled during the second half of the
study, obesity, prophylaxis discontinuation during hospi-
talization, the presence of contraindications for pharma-
cologic prophylaxis, and discharge diagnosis (p < 0.10).
Table 1 Baseline characteristics of patients whose
prescriptions were included in the study (n = 310)
n (%) Mean
(SD)
Male Sex 149
(48.1)
Age 66.2 (20.1)
Diagnosis
Infections 124
(39.9)
Neurological disorders 40 (12.9)
Gastrointestinal diseases 31 (10)
Electrolyte disturbances 25 (8.1)
Cancer/Chemotherapy 19 (6.1)
Respiratory diseases 16 (5.2)
Cardiac diseases 11 (3.5)
Others 44 (14.3)
Contraindication for pharmacologic
prophylaxis
54 (17.4)
Contraindication for GCS or IPC 5 (1.6)
Surgery 38 (12.6)
Major RF 103
(33.2)
Number of RF 2.8 (1.1)
Risk Group
A 97 (31.1)
B 86 (27.7)
C 92 (29.7)
D 6 (1.9)
E 29 (9.4)
SD = Standard Deviation
GCS = Graduated compression stockings
IPC = Intermittent pneumatic compression devices
RF = Risk factor
Figure 1 Frequency of prescriptions complying with VTE
prophylaxis institutional guideline and type of non-
appropriateness according to risk group (n = 310).
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received prophylaxis since the admission and those
admitted for gastrointestinal diseases (compared with
patients admitted for infectious conditions) were more
likely to have an appropriate VTE prescription. On the
contrary, the odds of inappropriateness in patients who
underwent surgery tripled that of patients who did not
require a surgical procedure. Patients in Groups C, E
and B had an increasingly higher risk of inappropriate
prescription compared with patients in Group A (Table
3).
Discussion
This study evaluated the appropriateness of the VTE
prophylaxis prescriptions according to local guidelines,
in medical general ward admitted patients of two teach-
ing hospitals of Buenos Aires. The analyzed prescrip-
tions belonged to patients at a high risk of VTE, since
less than 10% required no prophylaxis and patients had
in average 3 VTE-risk factors. Appropriate prescribing
Figure 2 Comparison between recommended and observed
prophylaxis (n = 310). UFH 10000 = unfractionated heparin 5000
IU every 12 hours. UFH 15000 = unfractionated heparin 7500 IU
every 12 hours or 5000 IU every 8 hours. Anti Xa = low molecular
weight heparin 4000 IU anti Xa/day. Mechanical = graduated
compression stockings or intermittent pneumatic compression
devices. None = No prescription for mechanical or pharmacologic
prophylaxis.
Table 2 Characteristics’ comparison between non-appropriate and appropriate prescriptions
Non-appropriate prescription
(n = 122)
n (%)
Appropriate prescription
(n = 188)
n (%)
p value
Male Sex 55 (45.1) 94 (50) 0.397
Age –Mean (SD) 65.22 (20.9) 66.85 (20.6) 0.501
Diagnosis 0.020
Infections 49 (40.2) 75 (39.9)
Neurological disorders 19 (15.6) 21 (11.2)
Gastrointestinal diseases 5 (4.1) 26 (13.8)
Electrolyte disturbances 9 (7.4) 16 (8.5)
Cancer/Chemotherapy 7 (5.7) 12 (6.4)
Respiratory diseases 6 (4.9) 10 (5.3)
Cardiac diseases 9 (7.4) 2 (1.1)
Others 18 (14.8) 26 (13)
Contraindications for pharmacologic prophylaxis 15 (12.3) 39 (20.7) 0.055
Surgery 24 (19.7) 14 (7.4) 0.001
Prophylaxis prescription upon admission 96 (78.7) 163 (88.2) 0.024
Obesity 12 (9.8) 9 (4.8) 0.084
Renal failure 21 (17.2) 29 (15.5) 0.676
Prophylaxis discontinuation during hospitalization 18 (14.8) 16 (8.5) 0.086
Stay at ICU during hospitalization 31 (25.4) 39 (20.7) 0.337
Study enrollment 0.020
First half 71 (58.2) 84 (44.7)
Second half 51 (41.8) 104 (55.3)
Risk Group 0.001
A 21 (17.2) 76 (40.4)
B 48 (39.3) 38 (20.2)
C 33 (27) 59 (31.4)
D 6 (4.9) 0 (0)
E 14 (11.5) 15 (8)
SD = Standard Deviation
ICU = Intensive care unit
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prescriptions were inappropriate, only 10% lacked all
prophylactic measure.
In agreement with previous studies, 90% of patients
had an increased risk for VTE [14,15,20]. However, the
rate of appropriateness observed in our population was
one of the highest reported in the literature
[14,15,20-23]. Nevertheless, differences with other
reports’ definitions and study-populations should be
considered. Most studies included both medical and sur-
gical patients or patients admitted in different hospital
areas such as the ICU, the emergency unit and the gen-
eral ward [14,15,20-22]. Still, the compliance with
recommendations observed in our study seems to be
comparatively high, especially if we take into account
that appropriateness in medical general wards is often
lower than that observed in other hospital areas [22].
The high rate of appropriateness observed may be
related to our institution’s large experience in thrombo-
prophylaxis. VTE-guidelines were implemented in 1999
and since then several actions have been taken for their
dissemination and update. Medical practice in university
hospitals, guidelines dissemination and their inclusion in
everyday practice were previously reported as variables
associated with a high rate of appropriateness [2,14,22].
The adherence rate was higher when measured
according to ACCP recommendations than our institu-
tion’s guidelines. This was due to the fact that our CPG
were more specific in the type of prophylactic measure
recommended than those listed in the ACCP conference
[10].
Appropriately or not, 85% of the patients received
thromboprophylaxis, indicating the importance that phy-
sicians give to VTE-prophylaxis in our institution. The
lower level of accurate prophylaxis prescribing may
reveal the lack of detailed knowledge of the institutional
recommendations or the presence of complex guidelines
resulting in low compliance.
When appropriateness is analyzed according to the
different risk groups established by the guidelines, we
can observe: (1) a high rate of appropriateness in the
g r o u pa tah i g h e s tr i s k ;( 2 )p o o rc o m p l i a n c ew i t hc o m -
plex prophylaxis measures, such as the combination of
pharmacologic and mechanical measures; (3) difficulties
in risk groups classification according to the number of
risk factors; and (4) difficulties in the detection of
patients at a lower risk (high rate of excessive prescrib-
ing in group E and absent prescribing in group C). This
suggests that there is a need of simpler guidelines, easier
to understand and remember.
Among the analyzed variables, thromboprophylaxis
prescribing upon admission showed a significant asso-
ciation with appropriateness. Since there is a high rate
of patients at risk of VTE, the need of an accurate eva-
luation of the admitting physician becomes crucial.
From the patient-safety perspective, a systematic evalua-
tion at a well-defined moment of hospitalization favors
the implementation of recommendations. Surgery during
hospitalization was a risk factor for nonappropriate pre-
scribing. This could be due to the treating physicians’
concern about the risk of bleeding and a higher error
rate as a result of patients’ treatment by two different
health teams.
One strength of this study is its prospective design
which allowed an accurate examination of prescriptions
by qualified reviewers. The dates and times for patients’
evaluation were randomly selected to avoid sampling
errors, such as the exclusion of patients admitted by the
on call team, at weekends, or prescriptions evaluated
only after staff physicians’ supervision.
In addition, we analyzed the relationship between
appropriateness and variables related to the prescribing
physician, the patient, the setting where prescriptions
were issued and the type of prophylaxis used. The type
of error committed was also analyzed, including the pos-
sibility of a voluntary lack of compliance. This detailed
analysis allows the development of effective strategies to
achieve an improvement in VTE prophylaxis prescribing.
Table 3 Multiple logistic regression: predictors of non-
appropriate VTE-prophylaxis prescription
OR 95% CI p
Diagnosis #
Neurological disorders 1.814 0.808 - 4.072 0.149
Gastrointestinal diseases 0.188 0.052 - 0.681 0.011
Electrolyte disturbances 1.199 0.447 - 3.215 0.718
Cancer/Chemotherapy 2.851 0.819 - 9.930 0.100
Cardiac diseases 5.170 0.901 - 29.658 0.065
Respiratory diseases 0.838 0.238 - 2.951 0.783
Others 0.973 0.414 - 2.290 0.950
Contraindications for pharmacologic
prophylaxis
0.696 0.315 - 1.538 0.371
Surgery 3.410 1.346 - 8.635 0.010
Prophylaxis prescription upon admission 0.419 0.199 - 0.881 0.022
Obesity 1.941 0.697 - 5.408 0.204
Prophylaxis discontinuation during
hospitalization
1.531 0.605 - 3.873 0.369
Enrollment during the second half of the
study
0.664 0.391 - 1.129 0.131
Risk Group*
B 5.317 2.369 -11.936 0.001
C 2.837 1.280 - 6.288 0.010
E 4.704 1.697 - 13.035 0.003
OR: Odds ratio
CI: Confidence interval
# Reference category: Infection
* Reference category: Group A
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stood considering some limitations.
First, the interviews with the head attending physician
m a yb ec o n s i d e r e da sa ni n t e r v e n t i o ni t s e l f ,w i t ht h e
consequent impact on the appropriateness (Hawthorne
effect). Nevertheless, no significant changes were
observed when analyzing the appropriateness along the
study period. Second, as we evaluated each prescription
only once during a patient hospitalization, we could not
analyze appropriateness after a long period of hospitali-
zation. This potential bias is minimized, given that only
25% of patients were hospitalized for more than 7 days,
and the time period between each examination day was
variable due to randomizatio n .T h i r d ,a sw ea n a l y z e d
compliance with our institutional guidelines, external
validity may be affected. Still, the evaluation of appropri-
ateness according to ACCP guidelines led to important
improvement of guideline’s adherence.
We consider that the detailed information generated
by this study will allow the design of strategies to
improve compliance with guidelines, and to analyze the
effectiveness of the implemented measures. Moreover, a
regular provision of feedback to those involved in the
prescription of VTE-prophylaxis, would lead to a contin-
uous quality improvement. Last, the VTE-prophylaxis
appropriateness provides a truthful indicator of health
care quality and patient safety.
Conclusions
VTE prophylaxis is usually prescribed in our general
ward inpatients, but appropriateness according to guide-
lines is less frequently observed. Despite the high level of
appropriateness, improvements are still possible. Simpler
guidelines and effective implementation strategies are
necessary to reduce errors in prophylaxis prescriptions.
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